Background

• A rare type of tumor, named gastroenteropancreatic neuroendocrine tumor (GEP-NET), previously known as gastrointestinal carcinoids, was given by Oberndorfer in the 18th-19th century, which grows in the areas of the gut or pancreas. This kind of tumor is generally located in the rectum or colon, ileum, jejunum, esophagus, stomach, pancreas, duodenum, jejunum, and appendix, together known as GEP-NET. This kind of tumor arises from the neuroendocrine cells, both within the cells of the diffuse endocrine system and the endocrine organs, known to be neoplasms of the heterogenous groups in which few may be indolent, and others may be fatal and aggressive.  
• GEP-NET can be of functioning that includes somatostatinoma, gastrinoma, VIPoma, glucagonoma, and insulinoma, and non-functioning forms of GEP-NET point to hormonal hypersecretion where clinical syndromes are absent. GEP-NET has a general classification, such as uncertain or well-differentiated with benign, poorly differentiated with high-grade malignant behavior, or well-differentiated with low-grade malignant. 

Epidemiology

• Incidence and Prevalence: 
• Incidence of GEP-NETs worldwide is estimated to be 1-5 new cases per 100000 people with an average age of 61.4 years at diagnosis, which is on the rise over the years and contribute 0.5% of all malignancies newly diagnosed, are rare, and relatively low when compared with other cancer types in which its prevalence can be varied regionally depending on the population. North America and Europe show the most cases of GEP-NETs, which are common in a few regions. Due to awareness and advances in diagnostic procedures in recent years, the incidence of GEP-NETs is increasingly increasing, where it is giving way to explore areas on how to treat them.  
• The prevalence of GEP-NETs is not estimated as these are rare tumors with low incidence previously and rising over the years. It can be noted that this kind of tumor develops slowly, and we don’t find any symptoms in the early or starting stages. Prevalence and specificity to GEP-NETs vary in which non-functional forms with well-differentiated subtype is common. Advances in diagnostic and imaging techniques pave the way to identify more common incidental or asymptomatic GEP-NETs. The varied nature of GEP-NETs with their clinical presentation, these are managed or taken care of by a team of oncologists, surgeons, gastroenterologists, and endocrinologists. 
• Age and Gender: 
• In Individuals between 50 and 70, GEP-NETs are diagnosed most, but it can occur in any age group, from pediatrics to geriatrics. Women are most affected by pancreatic NETs, and diagnosis is made commonly in adults, depending on the site and subtype. 
• Low-grade tumors can be seen at older ages, and high-grade fatal and aggressive tumors can be seen at younger ages. Carcinoid tumor in the appendix is the most common GEP-NETs in pediatrics. 
• Rectal and pancreatic NETs are seen more in women than in men, but gastric NETs share an equal percentage. NETs of small intestines are seen more in men. The prevalence of functional tumors varies by gender differences, whereas pancreatic NETs are an example where women are more prone to get affected. 
• Tumor sites: 
• Distribution of GEP-NETS can be varied, with the most common in the small intestine followed by the rectum and pancreas. 
• Functional and Non-Functional GEP-NETs: 
• Clinical syndromes with distinct natures are functional tumors that secrete hormones, and there are no clinical syndromes for non-functional tumors. 
• Syndromes: 
• Functional GEP-NETs with clinical syndromes include somatostatinoma, gastrinoma, VIPoma, glucagonoma, and insulinoma. 
• Genetic Predisposition: 
• Genetic predisposition is shown by few individuals to develop GEP-NETs, such as von Hippel-Lindau (VHL) syndrome and multiple endocrine neoplasia type 1 (MEN1), naming a few which are genetically associated with the risk of developing GEP-NETs. 

Anatomy

Pathophysiology

• Neuroendocrine cells and their function:  
• Throughout the digestive system, there are specialized cells named neuroendocrine cells, which also exhibit their presence in the endocrine system, lungs, and skin. They are characterized by both hormone-producing cells of the endocrine and neurons, where they show a variety in the production and secretion of hormones, neurotransmitters, and neuropeptides into the bloodstream, where physiological processes are regulated by acting as chemical messengers. These cells play a pivotal role in the digestive system in which functions take place, such as motility control, the release of digestive enzymes, and gastric acid secretion. 
• GEP-NETs pathophysiology is exhibited when neuroendocrine cells transform into neoplasms, which acquire other abnormalities along with genetic mutations, leading to uncontrolled tumor formation along with cell growth. Hormone production depends on the site and type of the GEP-NETs in which carcinoid tumors secrete serotonin and insulin, somatostatin, and glucagon, or gastrin, which pancreatic NETs produce. Overproduction of hormones presents its clinical syndrome in GEP-NETs, where, for example, symptoms in carcinoid syndrome, such as wheezing, diarrhea, and flushing, are associated with serotonin-secreting tumors. 
• Cell surfaces show receptors for somatostatin hormone in most GEP-NETs, which can stop the production of other hormones, which also has implications for therapeutics by peptide receptor radionuclide therapy and somatostatin analogs to target GEP-NETs.Top of Form 
• Neuroendocrine cell differentiation and transformation: 
• Transformation of normal neuroendocrine cells into neoplasms in GEP-NETs resulted from specific genetic mutations in which mTOR, ATRX, DAXX, and MEN1 pathway genes are common, and there are varied alterations of genes depending on the site and subtype of tumors. Tumor grade determination involves the degree of cell proliferation, which shows its aggressiveness in cell growth and division.  
• Tumors show the degree of differentiation in GEP-NETs by producing the specific hormone, which is related to its expected function and results in associated distinct clinical syndromes. The behavior of GEP-NETs depends on genetic mutations, tumor grade, and stage, ranging from slow-growing tumors that are indolent to aggressive forms, which are more rapid to invading tissues surrounding them and distributing their tumor form to distant organs. Ongoing research into cellular and molecular mechanisms provides insights and understanding of these advances, which can lead to more future targeted therapies for NETs. 
• Hormone Secretion:  
• Most GEP-NETs are functional, and hormones produced are site-specific and type-specific of the tumor in which insulin, somatostatin, glucagon, or gastrin are produced by pancreatic NETs, which results in the presentation of distinct clinical syndromes Zollinger-Ellison syndrome or insulinoma syndrome. 
• Tumor Grading and Staging: 
•  Based on the histological features of GEP-NETs, tumor grade, and stage are classified in which grading shows its aggressiveness in cell growth and division, and staging helps in the determination of the tumor spread extent inside the body, whether distant organs or location or nearby lymph nodes. 
• Cell Proliferation and Mitotic Activity: 
• Cell proliferation and mitotic activity influence the behavior of the tumor and its grade in GEP-NETs, in which aggressive behavior of tumors shows its grade with higher mitotic rate and cell proliferation.  
• Heterogeneity: 
• Location and subtype of tumors show heterogeneity for GEP-NETs and show varying pathophysiology with varied behaviors and diverse characteristics, exhibiting challenges in the diagnosis and management. 

Etiology

• Genetic Predisposition: 
• Specific genetic syndromes and their alterations are associated with an increased risk of GEP-NETs which includes Tuberous Sclerosis Complex (TSC) linked to development of pancreatic NETs, Multiple Endocrine Neoplasia Type 1 (MEN1) individuals have more risk to develop pancreatic NETs in particular and GEP-NETs in general, von Hippel-Lindau (VHL) syndrome is associated with pancreatic NETs and other type of tumors, and Neurofibromatosis Type 1 (NF1) in few individuals they develop GEP-NETs. 
• Sporadic GEP-NETs: 
• In most cases, there is sporadic occurrence of GEP-NETs independent of any genetic predisposition. Somatic mutations or other genetic mutations, to some extent, occur spontaneously, but the exact reason for sporadic GEP-NETs is unknown. 
• Genetic Mutations: 
• Few gene somatic mutations in GEP-NETs have been identified, such as ATRX, MEN1 gene, and DAXX, which are associated with pancreatic NETs. 
• Epigenetic Changes: 
• Gene expression in the development of GEP-NETs is influenced by histone modifications and DNA methylation, which are epigenetic alterations. 
• Hormonal Factors: 
• Overproduction of certain specific hormones and their imbalances can lead to the pathogenesis of the disease. Zollinger-Ellison syndrome is caused by the production of gastrin in the pancreas, leading to gastrinomas. 
• Chronic inflammation and autoimmunity: 
• Chronic inflammation can be a contributing factor to the development of GEP-NETs in gastrointestinal tissue or pancreatic tissue, and autoimmune disorders also play a role in GEP-NETs, which lead to inflammation. 
• Environmental Factors: 
• Exposure to toxins or carcinogens can lead to the development of GEP-NETs, which are not definitive causative agents. 
• Diet and Lifestyle: 
• There is no known indication of diet and lifestyle in the development of GEP-NETs. 

Genetics

Prognostic Factors

•  Tumor Grade: 
• The most important prognostic factor is the mitotic rate and Ki-67 index which helps in the determination of tumor grade and shows tumor cells rapidness in their growth and division. High-grade G3 tumors are aggressive and associated with poor prognosis, and low-grade G1 tumors have good prognosis than intermediate (G2) and high-grade (G3)tumors. 
• Tumor Stage: 
• Tumor and its extent of spread inside the body refer to the tumor stage, which is assessed using the TNM (Tumor, Node, Metastasis) system and involves pathology and imaging evaluations. Localized primary tumors that are in the early stage have a prognosis than those that have spread to other lymph nodes and distant organs (metastatic). 
• Tumor size: 
• Prognosis can be influenced by the size of the tumor, with favorable outcomes in smaller tumors, while the worst prognosis is with larger tumors. 
• Location: 
• The primary site being in the pancreas or digestive system could affect the prognosis, which determines specific symptoms, growth rate, and treatment. 
• Functional vs Non-functional: 
• Functional tumors secrete hormones leading to clinical syndromes, which may affect the prognosis based on the complications and their severity. 
• Histological Subtype: 
• Each subtype has varied behaviors and treatment responses. 
• Ki-67 Index: 
• It is a cell proliferation marker with a higher index that reflects a more aggressive tumor with a poor prognosis. 
• Surgical Resection Status: 
• Its completeness is a crucial factor in which R0 (complete removal) resection gives a good prognosis compared to R2 or R1 resections (incomplete). 
• Metastasis: 
• Metastases’ presence in distant organs like the liver can impact the prognosis significantly. The metastatic disease is generally associated with the worst prognosis. 
• Age and General Health: 
• The ability to tolerate treatment and overall prognosis can be influenced by age and general health. 
• Genetic syndromes: 
• Association of GEP-NETs with Genetic syndromes can impact the prognosis. 
• Response to treatment: 
• Treatment response of the tumors can impact the prognosis, which includes surgery, peptide receptor radionuclide therapy, targeted therapies, and somatostatin analogs. 

Clinical History

• Symptomatic Presentation: 
• Clinical history can be varied in the case of GEP-NETs, which are often associated with the location of the tumor and its hormone production. 
• Functional tumors can lead to distinct clinical syndromes such as Carcinoid Syndrome, which exhibits symptoms such as diarrhea, flushing, valvular heart disease, and bronchoconstriction (serotonin-secreting tumors). Insulinoma syndrome presents with hypoglycemia and symptoms such as palpitations, sweating, and confusion (insulin-secreting tumors). 
• Zollinger-Ellison Syndrome is associated with abdominal pain, peptic ulcers, and gastroesophageal reflux disease—other syndromes associated with the overproduction of hormones or peptides. 
• Non-functional GEP-NETs may cause symptoms which are related to the size and location of tumors, symptoms such as weight loss, abdominal pain, or bowel obstruction. 
• Asymptomatic or Indolent Stage:  
• Most GEP-NETs low-grade or nonfunctional tumors, in particular, are indolent and remain asymptomatic for an extended period. This can be discovered during an unrelated medical evaluation, such as imaging for another condition. 
• Diagnosis and Staging: 
• Patients are evaluated for GEP-NETs following the onset of signs and symptoms or incidental findings. 
• Diagnostic tests may include imaging (CT, MRI, endoscopy), blood tests (chromogranin A, hormone levels), and tissue biopsies. 
• Staging determines the extent of the spread of disease, including whether it is localized or to nearby lymph nodes or distant organs. 

Physical Examination

• General Assessment: 
• Vital signs such as blood pressure, respiratory rate, heart rate, and body temperature are assessed. 
• Weight and Body Mass Index (BMI): 
• Changes in weight and BMI can indicate the progression of the disease in GEP-NETs, where unexplained weight loss or gain may recommend further investigations. 
• Physical Appearance: 
• While evaluating the physical appearance of the patients, associated clinical signs with specific GEP-NET syndromes can be revealed with the presence of symptoms such as edema, skin rash, or flushing indicative of carcinoid syndrome. 
• Abdominal Examination: 
• Abdominal examination should be performed thoroughly to assess signs of abdominal pain, palpable masses, or tenderness where importance is given to detecting tumors in the pancreas and gastrointestinal system. 
• Assessment for hepatomegaly and splenomegaly is recommended, which is related to metastatic disease. 
• Skin Examination: 
• Flushing or telangiectasia, which comes under skin changes, is associated with certain GEP-NETs and may be assessed during the examination. 
• Lymph Node Examination: 
• The presence of enlarged lymph nodes, especially in the area’s proximity to the site of the tumor, could be a sign of regional metastasis. 
• Neurological Examination: 
• Patients with functional syndromes of GEP-NETs, like insulinoma, can be assessed for consciousness and neurological function who experience hypoglycemic events. 
• Hormone-Related Signs: 
• Excessive production of hormones leads to specific clinical syndrome, which presents its signs such as hyperglycemia in insulinoma, diarrhea in carcinoid syndrome, and peptic ulcer symptoms in Zollinger-Ellison syndrome. 
• Physical Performance and Functional Status: 
• The ability of the patient to tolerate treatment and maintain a good quality of life depends on assessing their physical performance and functional status, which is essential. 
• Review of systems: 
• Any symptoms or alterations in different body functions that might be connected to the GEP-NETs, such as bowel habit changes, cardiovascular problems, or respiratory symptoms, might be found with a thorough system review. 
• Assessment of complications: 
• Clinicians may assess illness-related consequences, such as bowel obstruction, carcinoid heart disease, or other metastatic-related problems, in patients with advanced GEP-NETs. 
• Psychological Assessment: 
• Evaluation of the patient’s psychological and emotional state is crucial since GEP-NET diagnosis and treatment can have a major effect on mental health and quality of life. 

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

• Duodenal and Gastric Ulcers: 
• Symptoms of peptic ulcers, which can be brought on by an infection with Helicobacter pylori or by taking non-steroidal anti-inflammatory medicines (NSAIDs), include gastrointestinal bleeding, abdominal pain, and occasionally symptoms like those of Zollinger-Ellison syndrome. 
• IBS, or irritable bowel syndrome: 
• Chronic abdominal pain, bloating, and altered bowel habits are symptoms of IBS that can be confused with GEP-NETs symptoms, particularly in cases when the tumor is non-functional. 
• IBD, or inflammatory bowel disease: 
• Abdominal discomfort, diarrhea, and weight loss are symptoms of conditions such as Crohn’s disease and ulcerative colitis that can coincide with GEP-NETs symptoms. 
• Disorders of the Pancreas: 
• Pancreatic GEP-NETs may exhibit symptoms similar to those of other pancreatic disorders, including jaundice and abdominal pain. These conditions include pancreatic cysts, pancreatic adenocarcinoma, and chronic pancreatitis. 
• Gallstones and cholecystitis: 
• Abdominal pain in the right upper quadrant may be caused by gallstones or acute or chronic gallbladder inflammation (cholecystitis), which should be distinguished from pancreatic NETs. 
• Functional Endocrine tumors: 
• Sweating, palpitations, and diarrhea are symptoms that are similar to those of functional GEP-NETs in conditions like hyperthyroidism and pheochromocytoma. 
• Appendicitis: 
• Abdominal pain in the right lower quadrant may be a symptom of acute appendicitis, and it may resemble symptoms of GEP-NETs in the appendix or small intestine. 
• Diverticulitis: 
• Lower abdominal pain, fever, and changes in bowel habits can all be symptoms of diverticulitis, an infection or inflammation of diverticula in the colon. 
• Lymphoma: 
• Sometimes the symptoms of GEP-NETs and abdominal lymphoma might be mistaken, particularly when lymphadenopathies are present. 
• Gastrointestinal disorders that are functional: 
• GEP-NET symptoms might be confused with those of other conditions such as functional dyspepsia, gastroesophageal reflux disease (GERD), and functional bowel problems. 
• Gastrointestinal Bleeding: 
• Several illnesses, including as ulcers, angiodysplasia, and varices, can result in gastrointestinal bleeding, which can cause symptoms like melena (black, tarry stools) or hematochezia (bloody stool). 

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

• Surgery: 
• The main course of treatment for localized GEP-NETs is surgical resection. When feasible, the primary tumor and nearby lymph nodes are removed. 
• The location, size, and presence of metastases of the tumor all determine the extent to which surgery is required. 
• In particular cases, procedures such as minimally invasive surgery and endoscopic resection might be taken into consideration. 
• Medical Management: 
• In the treatment of GEP-NETs, medical measures are employed for multiple purposes: 
• Somatostatin Analog Therapy: By blocking the release of hormones, somatostatin analogs like octreotide and lanreotide can reduce symptoms associated with excess hormone production and slow the growth of tumors. 
• Targeted Therapies: In advanced GEP-NETs, angiogenesis and cell signaling pathways may be inhibited by medications such as sunitinib and everolimus. 
• Peptide Receptor Radionuclide Therapy (PRRT): PRRT targets and treats GEP-NETs with somatostatin receptors by employing radiolabeled somatostatin analogs. 
• Chemotherapy: In cases when other therapies are ineffective or for high-grade (G3) GEP-NETs, chemotherapy may be recommended. 
• Immunotherapy: Research on immunotherapies is still being conducted in the context of GEP-NET treatment. 
• Therapies Focused on the Liver: 
• Liver-directed therapy may be used to treat GEP-NETs that have spread to the liver. These include liver surgery (resection or ablation), radioembolization, and transarterial chemoembolization (TACE). 
• The goals of these treatments are to improve liver function and manage liver metastases. 
• Peptide Receptor Radionuclide Therapy (PRRT): 
• PRRT is a targeted therapy that delivers radiation to GEP-NET cells while sparing healthy tissue. It works by using radiolabeled somatostatin analogs. 
• When treating GEP-NETs with somatostatin receptor expression, like those seen in the pancreatic and small intestine, it works especially well. 
• Systemic Therapy for Functional Tumors: 
• Therapy may be necessary to manage symptoms related to hormones in functional GEP-NETs that produce excess hormones. Analogs of somatostatin are frequently used for this purpose. 
• Monitoring and Surveillance: 
• In order to evaluate therapy response, identify disease recurrence, and control adverse effects of medicines, ongoing surveillance and monitoring are crucial post-treatment. 
• Clinical Trials: 
• For GEP-NETs patients, clinical trial participation is frequently taken into consideration because continuous research can make cutting-edge therapies and medications available. 
• Supportive Care: 
• During GEP-NETs treatment, supportive care measures such as as pain management, nutritional support, and psychological support are vital in helping the patient have a better quality of life. 
• Multidisciplinary Team: 
• A multidisciplinary approach incorporating experts in radiology, pathology, endocrinology, gastroenterology, cancer, and surgery is beneficial for GEP-NETs care.  

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

lifestyle-modifications-in-treating-gep-nets

• Dietary Changes: 
• Dietary Modifications: Dietary adjustments may be required, depending on the individual symptoms and the tumor’s functional status. Patients with carcinoid syndrome, for instance, would need to stay away from triggers like alcohol and specific foods. 
• Balanced Diet: A well-balanced diet that prioritizes fruits, vegetables, whole grains, lean meats, and other nutrients will assist preserve general health. 
• Small, Frequent Meals: In situations of insulinoma, eating smaller, more frequent meals might help control symptoms like diarrhea and avoid blood sugar fluctuations. 
• Hydration 
• Drinking enough water is crucial, particularly for those who have diarrheal functional GEP-NETs. It’s vital to keep the fluid balance correct. 
• Exercise and Physical Activity: 
• Frequent exercise can lessen weariness, increase physical fitness, and assist in stress and anxiety management. 
• Exercise regimens should be customized for each patient based on their physical capabilities and health status; seeking advice from a physical therapist or healthcare professional is advised. 
• Stress Reduction: 
• Deep breathing, mindfulness, and meditation are examples of relaxation practices that can help patients manage their stress and lessen their symptoms. 
• Adherence to Medication: 
• Taking somatostatin analogs or other prescribed drugs as directed is crucial for managing symptoms and delaying the course of the illness. 
• Symptom Management: 
• Patients experiencing pain, diarrhea, or flushing should carefully collaborate with their healthcare team to treat specific GEP-NET-related symptoms. 
• Supportive Care: 
• Patients coping with the psychological and emotional effects of GEP-NETs may find it helpful to receive counseling and emotional support. 
• Patient advocacy groups and support groups can offer a network for exchanging experiences, getting information, and getting help. 
• Regular Follow-Up and Monitoring: 
• Maintaining a consistent follow-up plan with medical professionals is crucial for tracking the disease’s progression and the efficacy of treatment. 
• Weight Management: 
• It’s crucial to keep your weight in check. It’s important to manage nutrition because unexplained weight loss may be a symptom for some GEP-NETs. 
• Alcohol and Quitting Smoking: 
• It is recommended to cut back on alcohol intake or give up smoking, as these behaviors might aggravate symptoms and raise the possibility of certain complications. 
• Medication and Supplements: 
• All medications, including over-the-counter drugs and supplements, should be discussed with the patient’s medical team because some may interfere with GEP-NET therapies or symptoms. 
• Occupational Considerations: 
• Patients may need to talk about modifications and concerns at work, particularly if their illness and treatment make it difficult for them to work. 
•  

Role of Somatostatin Analogs in treating GEP-NETs

• Medication: lanreotide (Somatuline), octreotide (Sandostatin) 
• Administration: Subcutaneous (under the skin) or intramuscular injections are the usual ways in which these medications are given. One may administer long-acting formulations once every few weeks.  
• lanreotide: lanreotide functions by imitating the action of somatostatin, an endogenous hormone that is naturally produced by the body and which blocks the production of growth hormone as well as several gastrointestinal hormones. 
• octreotide: octreotide functions by emulating the effects of somatostatin, an endogenous hormone that blocks the release of growth hormone, insulin, and gastrointestinal hormones. 

Effectiveness of Targeted Therapies in treating GEP-NETs

• Medication: lenvatinib (Lenvima), everolimus (Afinitor), and sunitinib (Sutent) 
• Administration: Oral drugs administered by mouth in the form of tablets or capsules is referred to as targeted therapies. 
• lenvatinib: A multikinase inhibitor called lenvatinib targets many kinases linked to tumor growth and angiogenesis, the process that forms new blood vessels. lenvatinib helps lower the blood supply to tumors and slows down their growth by blocking these kinases. 
• everolimus: Since the mTOR protein is a major regulator of cell growth, proliferation, and survival, everolimus is a mTOR inhibitor. everolimus inhibits the proliferation of cancer cells and the formation of blood vessels in tumors by inhibiting the mTOR pathway. 
• sunitinib: Angiogenesis, or the formation of new blood vessels, and the tumor microenvironment are all targets of the receptor tyrosine kinase inhibitor sunitinib. sunitinib aids in reducing the blood flow to tumors and slowing the development of cancer cells by blocking these kinases. 

Role of Peptide Receptor Radionuclide Therapy (PRRT) in treating GEP-NETs

• Medicine: lutetium Equipped with Lu 177 (Lutathera) 
• Administration: An intravenous infusion of PRRT is given. Utilizing radiolabeled somatostatin analogs, which target neuroendocrine tumor cells selectively, is part of it. 
• lutetium Equipped with Lu 177: In nuclear medicine, lutetium-177 (Lu-177) is a radioactive isotope of the element lutetium that is utilized for a variety of therapeutic purposes, most notably targeted radionuclide therapy. 

Role of Chemotherapy in treating GEP-NETs

• Medication: 5-fluorouracil, cisplatin, etoposide, temozolomide, doxorubicin, and streptozocin 
• Chemotherapy is usually given intravenously, frequently as part of combination regimens. The GEP-NET’s type and stage determine the specific regimen and dose schedule. 
• 5-fluorouracil: A pyrimidine analog that obstructs DNA synthesis and cell division. It is integrated into cancer cells’ DNA and RNA, disrupting their capacity to divide and proliferate. In the final stage, this ends up resulting in cell death. 
• cisplatin: A platinum-containing substance called cisplatin creates extremely reactive chemicals in cancer cells. 
• etoposide: etoposide acts by obstructing topoisomerase II’s normal functioning, an enzyme that aids in regulating DNA shape and function. 
• temozolomide: temozolomide is a prodrug, which means that the body transforms it into its active form. The medication’s active form methylates DNA, causing damage to DNA and stopping cancer cells from proliferating. In the end, this results in cell death. 
• doxorubicin: Chemotherapy drugs such as doxorubicin, sometimes referred to as hydroxydaunorubicin, are used to treat different kinds of cancer. 
• streptozocin: Because streptozocin is an alkylating agent, it prevents cancer cells’ DNA from replicating and repairing effectively. 

Role of immunotherapy in treating GEP-NETs

• Medication: nivolumab (Opdivo), pembrolizumab (Keytruda), and atezolizumab (Tecentriq) 
• Administration: In a hospital or clinic setting, immunotherapy medications are given intravenously as infusions. 
• nivolumab: One drug in the class of medications known as immune checkpoint inhibitors is nivolumab. Designed to strengthen the body’s immune response against cancer cells, it is used to treat several types of cancer. 
• pembrolizumab: The immune checkpoint inhibitor pembrolizumab functions by preventing T cells from expressing the programmed cell death protein 1 (PD-1) receptor. 
• atezolizumab: An immune checkpoint inhibitor called atezolizumab prevents tumor cells from expressing programmed cell death-ligand 1 (PD-L1). This interaction stops PD-L1 from attaching to T cell receptor PD-1. atezolizumab aids in T cell activation by preventing this interaction, which enables the immune system to identify and combat cancer cells. 

Role of Hormone Replacement Therapy in treating GEP-NETs

• Medication: Antidiarrheal drugs, insulin for insulinoma or other antidiabetic drugs, and electrolyte replacement for some disorders (e.g., carcinoid syndrome or VIPoma syndrome). 
• Administration: To treat particular symptoms and hormone imbalances, these drugs are given orally or by injection as needed. 

Role of Supportive Medications in treating GEP-NETs

• Drugs: Painkillers, antiemetics for nausea and vomiting, and other supportive drugs to control GEP-NETs side effects or symptoms. 
• Administration: Depending on the individual symptoms, supportive drugs may be administered orally, intravenously, or by other appropriate routes. 

surgical-intervention-in-treating-gep-nets

• Primary Tumor Resection: For localized GEP-NETs, surgical excision of the main tumor is a typical treatment strategy. Whenever feasible, a full resection (R0) is the desired outcome. 
• The location of the tumor determines the exact surgical approach. For instance, pancreatic NETs may require distal pancreatectomy or pancreaticoduodenectomy (a Whipple procedure), whereas small intestine NETs may be removed by laparoscopic resection. 
• Lymph Node Dissection: When removing the primary tumor, lymph nodes that may contain metastatic disease are evaluated and removed using lymph node dissection. 
• Debulking Surgery: As much of the tumor as feasible is removed during debulking surgery, particularly in situations with metastatic GEP-NETs where complete resection is not possible. 
• The goals of debulking surgery are to decrease the size of the tumor, relieve symptoms, and increase the efficiency of existing treatments. 
• Liver Metastases Resection: When it is technically possible and expected to have a positive clinical outcome, surgically resecting liver metastases in GEP-NETs with these lesions may be considered. 
• Liver metastases can also be managed with a variety of liver-directed techniques, including transarterial therapy and ablation. 
• Appendectomy: An appendix removal (appendectomy) is the usual course of treatment for appendiceal NETs (also known as appendiceal carcinoids). 
• Radioguided Surgery: To help remove GEP-NETs expressing somatostatin receptors, radiolabeled somatostatin analogs may be used in radioguided surgery. 
• Enucleation: A surgical procedure called enucleation is applied to tiny, well-circumscribed pancreatic NETs. It entails taking out the tumor while protecting the pancreatic tissue around it. 
• Functional NET Syndromes: Hormone-secreting tumor-induced functional disorders can be treated surgically. For instance, excision may be necessary for gastrinomas causing Zollinger-Ellison syndrome, but pancreatic surgery, either partial or total, can be used to treat insulinomas. 

phases-in-managing-gep-nets

• Diagnosis and Evaluation:  
• Diagnosis: Identifying GEP-NETs is the first step. It can be initiated by surveillance in people with known genetic disorders, incidental findings, or symptoms. 
• Evaluation: In order to confirm the diagnosis and ascertain the tumor’s features (type, grade, stage, and hormone production), a comprehensive evaluation includes clinical assessments, imaging (such as CT, MRI, and endoscopy), tests in the laboratory, and tumor biopsy. 
• Staging and Grading: 
• To evaluate the aggressiveness of the tumor and the degree of the disease, staging and grading are crucial. For staging, the TNM approach (tumor, node, metastasis) is frequently employed; the Ki-67 index and mitotic rate are utilized for grading. 
• Treatment Strategy: 
• A treatment plan is created based on the features of the tumor, such as its type, grade, and stage. A multidisciplinary team of experts, including surgeons, gastroenterologists, endocrinologists, and oncologists, may be involved in this phase. 
• Surgery: 
• In many cases, surgical resection is advised for localized GEP-NETs. The location, size, and likelihood of complete tumor removal determine the extent to which surgery is required. 
• Medical Management: 
• Medical treatments such as somatostatin analogs, targeted medicines, chemotherapy, and peptide receptor radionuclide therapy (PRRT) may be used to reduce symptoms and slow tumor growth, depending on the type and functional status of the tumor. 
• Liver-Directed Therapies: 
• Liver-directed therapy, including as transarterial chemoembolization (TACE), radioembolization, and liver surgery, may be used for controlling liver involvement in GEP-NETs with liver metastases. 
• Symptom Management: 
• For patients who have functional GEP-NETs in particular, symptom management is an ongoing process. It covers prescription drugs and lifestyle adjustments to treat symptoms such as hormone imbalances, flushing, and diarrhea. 
• Long-Term Follow-Up and Monitoring: 
• In order to evaluate treatment response, detect disease recurrence, and manage potential adverse reactions and complications, regular follow-up and monitoring are essential. 
• Clinical Trials: 
• At various stages, taking part in clinical trials may be taken into consideration to investigate novel therapeutic techniques and treatments. 
• Supportive Care: 
• The goal of supportive care measures is to enhance the patient’s quality of life while undergoing treatment. These methods include management of pain, nutritional support, and psychological support. 
• End-of-Life Care: 
• Palliative and end-of-life care are being considered as a means of symptom management and comfort when GEP-NETs grow more aggressive or unresponsive to treatment. 
• Psychosocial and Emotional Support: 
• Patients may benefit from psychological and emotional support at any stage to help them deal with the difficulties and uncertainties that come with GEP-NETs. 

Medication

Future Trends

Media Gallary

References

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111010/